ADB-HEXINACA
ADB-HEXINACA is a synthetic cannabinoid that belongs to the indazole-3-carboxamide family. It is a potent agonist of the cannabinoid receptors, specifically the CB1 and CB2 receptors. ADB-HEXINACA is often used in scientific research to study the effects of cannabinoids on the human body and the endocannabinoid system.
Chemical Structure[edit | edit source]
ADB-HEXINACA has a chemical structure that includes an indazole core, which is a common feature among synthetic cannabinoids. The full chemical name of ADB-HEXINACA is N-1-amino-3,3-dimethyl-1-oxobutan-2-yl-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide. The presence of the cyclohexylmethyl group distinguishes it from other synthetic cannabinoids.
Pharmacology[edit | edit source]
As a potent agonist of the CB1 and CB2 receptors, ADB-HEXINACA mimics the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. It binds to these receptors with high affinity, leading to various physiological and psychoactive effects. The exact pharmacokinetics and metabolism of ADB-HEXINACA are still under investigation.
Legal Status[edit | edit source]
The legal status of ADB-HEXINACA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. Researchers must obtain special licenses to study this compound legally.
Health Effects and Risks[edit | edit source]
The health effects and risks associated with ADB-HEXINACA are not fully understood. However, synthetic cannabinoids, in general, have been linked to severe adverse effects, including psychosis, tachycardia, and seizures. Long-term use may lead to dependence and other health complications.
Research Applications[edit | edit source]
ADB-HEXINACA is primarily used in scientific research to explore the endocannabinoid system and the potential therapeutic applications of cannabinoids. It helps in understanding the interaction between synthetic cannabinoids and cannabinoid receptors, which can lead to the development of new medications.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
